We are pleased to announce the start of dossier development for nasal Esketamine.
Based on the reference brand Spravato, Esketamine nasal spray has been approved in several regulated markets for adults with Treatment-Resistant Depression (TRD) in combination with an oral antidepressant.
Regulatory approvals also recognize its role in the rapid reduction of depressive symptoms in adults with moderate to severe Major Depressive Disorder (MDD) where symptoms are considered a psychiatric emergency.
Depression is one of the most significant unmet needs in global healthcare. Contact us to add Esketamine to your portfolio or to see our full range of neurology products.
Globally, an estimated 332 million adults experience clinically significant depressive disorders each year. Within this, Major Depressive Disorder (MDD) accounts for the majority of disability and disease burden associated with depression.
Clinical studies suggest that almost 50% of people with MDD do not respond adequately to at least two standard antidepressant treatments and are considered to have treatment-resistant depression (TRD).
A novel, fast-acting therapy
Esketamine has a rapid onset of action, with symptom improvement observed within hours to days, compared with conventional SSRI and SNRI antidepressants, which may take weeks to reach full effect.
As a nasal spray, Esketamine offers convenience through a small, portable, ready-to-use device designed for individualized dosing under supervised administration.
On target to become an important therapy
Progress towards generic nasal Esketamine comes at a critical time: the World Health Organization projects that by 2030, depression will become the single greatest contributor to the global burden of disease, surpassing heart disease and cancer in terms of total years of healthy life lost.
IQVIA figures indicate that the global market for nasal Esketamine had already surpassed $1.1 billion by Q2 2025, with a 59% CAGR.
To explore licensing and commercial opportunities for Esketamine or any other product in our neurology portfolio, contact a member of the team today.